West Pharmaceutical Services Inc (WST)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $29.01B
Last updated: Nov 17, 2026 at 11:06 AM ET
West Pharmaceutical Services Inc (WST) Earnings: Report Dates and Results
West Pharmaceutical Services (WST) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, West Pharmaceutical Services reported EPS of $2.66, above the $2.18 estimate. It beat the EPS estimate in each of the last 9 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
WST has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.2% above the $2.04 reported for the quarter ended Dec 31, 2025.
WST Earnings Call
The latest WST earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, WST beat 36 and missed 4. The widest gap in the table came in the quarter ended Mar 31, 2021, when EPS landed 43.36% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.66 | $2.18 | $2.16 - $2.23 | +22.02% | Beat | +35.7% | 14 | 1 up, 0 down | Oct 29, 2026 | N/A |
| Jun 30, 2026 | $2.37 | $2.08 | $2.05 - $2.10 | +13.94% | Beat | +28.8% | 14 | 0 up, 2 down | Jul 23, 2026 | $872.30M |
| Mar 31, 2026 | $2.13 | $1.68 | $1.65 - $1.69 | +26.79% | Beat | +46.9% | 12 | 0 up, 3 down | Apr 23, 2026 | $844.90M |
| Dec 31, 2025 | $2.04 | $1.83 | $1.79 - $1.88 | +11.48% | Beat | +12.1% | 13 | 2 up, 0 down | Feb 12, 2026 | $805.00M |
| Sep 30, 2025 | $1.96 | $1.71 | $1.65 - $1.72 | +14.62% | Beat | +5.9% | 12 | 1 up, 0 down | Oct 23, 2025 | $804.60M |
| Jun 30, 2025 | $1.84 | $1.54 | $1.43 - $1.54 | +19.48% | Beat | +21.1% | 12 | N/A | Jul 24, 2025 | $766.50M |
| Mar 31, 2025 | $1.45 | $1.26 | N/A | +15.08% | Beat | -7.1% | 8 | 1 up, 0 down | Apr 24, 2025 | $698.00M |
| Dec 31, 2024 | $1.82 | $1.71 | $1.64 - $1.78 | +6.43% | Beat | -0.5% | 9 | 0 up, 0 down | Feb 13, 2025 | $748.80M |
| Sep 30, 2024 | $1.85 | $1.49 | $1.46 - $1.57 | +24.16% | Beat | -14.4% | 9 | 0 up, 0 down | Oct 24, 2024 | $746.90M |
| Jun 30, 2024 | $1.52 | $1.73 | $1.54 - $1.94 | -12.14% | Miss | -28.0% | 9 | 0 up, 0 down | Jul 25, 2024 | $702.10M |
| Mar 31, 2024 | $1.56 | $1.29 | $1.20 - $1.34 | +20.93% | Beat | -21.2% | 8 | 0 up, 0 down | Apr 25, 2024 | $695.40M |
| Dec 31, 2023 | $1.83 | $1.78 | $1.73 - $1.86 | +2.81% | Beat | +3.4% | 8 | 0 up, 0 down | Feb 15, 2024 | $732.00M |
| Sep 30, 2023 | $2.16 | $1.86 | $1.80 - $1.94 | +16.13% | Beat | +6.4% | 8 | 0 up, 0 down | Oct 26, 2023 | $747.40M |
| Jun 30, 2023 | $2.11 | $1.93 | $1.85 - $2.13 | +9.33% | Beat | -14.6% | 8 | 0 up, 1 down | Jul 27, 2023 | $753.80M |
| Mar 31, 2023 | $1.98 | $1.67 | $1.50 - $1.83 | +18.56% | Beat | -13.9% | 8 | 2 up, 0 down | Apr 27, 2023 | $716.60M |
| Dec 31, 2022 | $1.77 | $1.38 | $1.34 - $1.41 | +28.26% | Beat | -13.2% | 8 | 1 up, 0 down | Feb 16, 2023 | $708.70M |
| Sep 30, 2022 | $2.03 | $2.12 | $2.08 - $2.17 | -4.25% | Miss | -1.5% | 6 | 0 up, 1 down | Oct 27, 2022 | $686.90M |
| Jun 30, 2022 | $2.47 | $2.21 | $2.11 - $2.26 | +11.76% | Beat | +0.4% | 6 | 0 up, 0 down | Jul 28, 2022 | $771.30M |
| Mar 31, 2022 | $2.30 | $2.12 | $2.00 - $2.26 | +8.49% | Beat | +12.2% | 6 | 1 up, 0 down | Apr 28, 2022 | $720.00M |
| Dec 31, 2021 | $2.04 | $1.92 | $1.90 - $1.94 | +6.25% | Beat | +52.2% | 6 | 0 up, 0 down | Feb 17, 2022 | $730.80M |
| Sep 30, 2021 | $2.06 | $1.80 | $1.72 - $1.85 | +14.44% | Beat | +79.1% | 6 | N/A | Oct 28, 2021 | $706.50M |
| Jun 30, 2021 | $2.46 | $1.74 | $1.68 - $1.85 | +41.38% | Beat | +96.8% | 6 | N/A | Jul 29, 2021 | $723.60M |
| Mar 31, 2021 | $2.05 | $1.43 | $1.36 - $1.50 | +43.36% | Beat | +103.0% | 6 | N/A | Apr 29, 2021 | $670.70M |
| Dec 31, 2020 | $1.34 | $1.13 | $1.11 - $1.18 | +18.58% | Beat | +63.4% | 6 | N/A | Feb 18, 2021 | $580.20M |
| Sep 30, 2020 | $1.15 | $0.99 | $0.95 - $1.02 | +16.16% | Beat | +45.6% | 5 | N/A | Oct 22, 2020 | $548.00M |
| Jun 30, 2020 | $1.25 | $0.92 | $0.85 - $0.92 | +35.87% | Beat | +40.4% | 4 | N/A | Jul 23, 2020 | $527.20M |
| Mar 31, 2020 | $1.01 | $0.82 | $0.79 - $0.85 | +23.17% | Beat | +36.5% | 5 | N/A | Apr 23, 2020 | $491.50M |
| Dec 31, 2019 | $0.82 | $0.72 | $0.70 - $0.74 | +13.89% | Beat | +12.3% | 5 | N/A | Feb 13, 2020 | $470.60M |
| Sep 30, 2019 | $0.79 | $0.71 | $0.69 - $0.72 | +11.27% | Beat | +3.9% | 5 | N/A | Oct 24, 2019 | $456.10M |
| Jun 30, 2019 | $0.89 | $0.72 | $0.71 - $0.75 | +23.61% | Beat | +27.1% | 5 | N/A | Jul 25, 2019 | $469.70M |
| Mar 31, 2019 | $0.74 | $0.66 | $0.64 - $0.67 | +12.12% | Beat | +19.4% | 6 | N/A | Apr 25, 2019 | $443.50M |
| Dec 31, 2018 | $0.73 | $0.72 | $0.71 - $0.73 | +1.39% | Beat | +14.1% | 6 | N/A | Feb 14, 2019 | $422.50M |
| Sep 30, 2018 | $0.76 | $0.70 | $0.66 - $0.73 | +8.57% | Beat | +13.4% | 6 | N/A | Oct 25, 2018 | $431.70M |
| Jun 30, 2018 | $0.70 | $0.67 | $0.63 - $0.72 | +4.48% | Beat | +6.1% | 6 | N/A | Jul 26, 2018 | $447.50M |
| Mar 31, 2018 | $0.62 | $0.64 | $0.62 - $0.65 | -3.13% | Miss | +3.3% | 7 | N/A | Apr 26, 2018 | $415.70M |
| Dec 31, 2017 | $0.64 | $0.63 | $0.61 - $0.68 | +1.59% | Beat | +18.5% | 8 | N/A | Feb 15, 2018 | $415.60M |
| Sep 30, 2017 | $0.67 | $0.53 | $0.51 - $0.54 | +26.42% | Beat | +26.4% | 7 | N/A | Oct 26, 2017 | $398.20M |
| Jun 30, 2017 | $0.66 | $0.65 | $0.63 - $0.67 | +1.54% | Beat | +11.9% | 6 | N/A | Jul 27, 2017 | $397.60M |
| Mar 31, 2017 | $0.60 | $0.56 | N/A | +7.14% | Beat | +13.2% | N/A | N/A | Apr 27, 2017 | $387.70M |
| Dec 31, 2016 | $0.54 | $0.56 | N/A | -3.57% | Miss | +14.9% | N/A | N/A | Feb 16, 2017 | $382.30M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $7.29, up 8.0% from the year before. It was $2.19 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $7.29 | +8.0% |
| Dec 31, 2024 | $6.75 | -16.5% |
| Dec 31, 2023 | $8.08 | -5.7% |
| Dec 31, 2022 | $8.57 | N/A |
| Dec 31, 2021 | $8.61 | +81.3% |
| Dec 31, 2020 | $4.75 | +46.6% |
| Dec 31, 2019 | $3.24 | +15.3% |
| Dec 31, 2018 | $2.81 | +9.3% |
| Dec 31, 2017 | $2.57 | +17.4% |
| Dec 31, 2016 | $2.19 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,000 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,982 | 16 | |
| 2026Q2 | Jun 30, 2026 | 7,661 | 15 | |
| 2026Q1 | Mar 31, 2026 | 7,538 | 14 | |
| 2025Q4 | Dec 31, 2025 | 5,721 | 8 | |
| 2025Q3 | Sep 30, 2025 | 6,644 | 16 | |
| 2025Q2 | Jun 30, 2025 | 6,438 | 17 | |
| 2025Q1 | Mar 31, 2025 | 8,742 | 16 | |
| 2024Q4 | Dec 31, 2024 | 8,511 | 13 |
2026Q3 Earnings Call
Opening remarks
Michele Polinsky Vice President of Communications Good morning, and welcome to West's third quarter earnings conference call, which has been webcast live. With me today on the call are West President and CEO, Michel Lagarde, and West Senior Vice President and CFO, Bob McMahon. Earlier today, we issued our third quarter financial results. A copy of the press release, along with today's slide presentation containing supplemental information for your reference, has been posted in the investors section of the company's website at investor.westpharma.com. Later today, a replay of the webcast will also be available in the investors section of our website. Before we begin, we'd like to remind you that statements made by management during this call and in the accompanying presentation contain forward-looking statements within the meaning of U.S. federal securities law. Please refer to the accompanying Safe Harbor statement in today's presentation and press release, in addition to other disclosures made by the company, such as our 10-K and 10-Q, regarding the risks to which the company is subject. During the call, management will also report on certain non-GAAP financial measures, including organic net sales, adjusted operating profit, adjusted operating profit margin, free cash flow, and adjusted diluted earnings per share. The accompanying disclosure statement, as well as reconciliations of these non-GAAP financial measures to the most comparable financial results prepared in conformity with U.S. GAAP, are provided in this morning's press release and today's presentation materials. I'll now turn the call over to our CEO, Michel Lagarde. Michel?
Michel Lagarde CEO Thank you, Michele, and good morning, everyone. Thanks for joining us today. We're very pleased to welcome you to our earnings call. Before getting into the details of our strong third quarter performance, I want to begin by saying what a privilege it is for me to now be part of Team West. Having joined West two months ago, my priority has been spending time with our global teams, visiting our sites around the world, and meeting with our customers and investors. It's been incredibly rewarding to connect and learn from the company's stakeholder network and start to identify how we can build on our strengths and continue to evolve. These have been valuable conversations, and I'd like to give a few examples. First was my visit to our Eschweiler manufacturing site in Germany. What was immediately apparent was a strong mission-driven culture and teamwork among the colleagues. Confronted with the need to increase output, the team focused on execution and unlocking new efficiencies, for instance, by integrating more automation onto the production floor. This effort is helping to expand capacity and support our global network optimization to improve the service levels for our customers.
Frequently Asked Questions About WST
When is West Pharmaceutical Services's next earnings date?
West Pharmaceutical Services's next earnings report is expected for Feb 10, 2027.
Did WST beat earnings estimates last quarter?
Yes. West Pharmaceutical Services reported EPS of $2.66 for the quarter ended Sep 30, 2026, above the $2.18 estimate, a 22.02% surprise.
What EPS do analysts expect from WST next quarter?
The consensus EPS estimate for West Pharmaceutical Services for the quarter ending Dec 31, 2026 is $2.31 from 13 analysts, with estimates from $2.19 to $2.44.
How often does WST beat earnings estimates?
West Pharmaceutical Services beat the EPS estimate in each of the last 9 quarters, with an average surprise of +17.11%.
WST pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors